Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Advertising and Sponsorship
    • Profile & Readership
    • Contact Us
    • Latest News
    • Privacy & Cookies Policies
    • Terms of Use
    • Advertising Terms
    • Issue 81
    • Issue 80
    • Issue 79
    • Issue 78
    • Issue 77
    • Issue 76
    • Issue 75
    • Issue 74
    • Issue 73
    • Issue 72
    • Issue 71
    • Issue 70
    • View All
    • About the Awards
    • Awards Timetable
    • Awards Winners
    • Submit Nominations
    • Testimonials
    • Media Room
    • FAQ
    • Asset Management Awards
    • Brand of the Year Awards
    • Business Awards
    • Cash Management Banking Awards
    • Banking Technology Awards
    • CEO Awards
    • Customer Service Awards
    • CSR Awards
    • Deal of the Year Awards
    • Corporate Governance Awards
    • Corporate Banking Awards
    • Digital Transformation Awards
    • Fintech Awards
    • Education & Training Awards
    • ESG & Sustainability Awards
    • ESG Awards
    • Forex Banking Awards
    • Innovation Awards
    • Insurance & Takaful Awards
    • Investment Banking Awards
    • Investor Relations Awards
    • Leadership Awards
    • Islamic Banking Awards
    • Real Estate Awards
    • Project Finance Awards
    • Process & Product Awards
    • Telecommunication Awards
    • HR & Recruitment Awards
    • Trade Finance Awards
    • The Next 100 Global Awards
    • Wealth Management Awards
    • Travel Awards
    • Years of Excellence Awards
    • Publishing Principles
    • Ownership & Funding
    • Corrections Policy
    • Editorial Code of Ethics
    • Diversity & Inclusion Policy
    • Fact Checking Policy
    Original content: Global Banking and Finance Review - https://www.globalbankingandfinance.com

    A global financial intelligence and recognition platform delivering authoritative insights, data-driven analysis, and institutional benchmarking across Banking, Capital Markets, Investment, Technology, and Financial Infrastructure.

    Copyright © 2010-2026 - All Rights Reserved. | Sitemap | Tags

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    1. Home
    2. >Finance
    3. >Novo, Lilly collaborate with Waltz Health to sell weight-loss drugs directly to employers
    Finance

    Novo, Lilly Collaborate With Waltz Health to Sell Weight-Loss Drugs Directly to Employers

    Published by Global Banking & Finance Review®

    Posted on November 21, 2025

    2 min read

    Last updated: January 20, 2026

    Add as preferred source on Google
    Novo, Lilly collaborate with Waltz Health to sell weight-loss drugs directly to employers - Finance news and analysis from Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Tags:innovationpartnershiphealthcareinsurancetechnology

    Quick Summary

    Waltz Health partners with Novo Nordisk and Eli Lilly to sell weight-loss drugs directly to employers, aiming to streamline access and pricing.

    Novo, Lilly Team Up with Waltz to Offer Weight-Loss Drugs to Employers

    (Reuters) -Digital health company Waltz Health said on Friday it has launched a program to offer popular weight-loss drugs from Novo Nordisk and Eli Lilly directly to employers, bypassing traditional drug sales channels.

    Waltz said employees can access the drugs through their existing healthcare providers or a telehealth option integrated into the program, which is expected to launch on January 1 next year.

    The direct-to-employer structure is designed to eliminate "unnecessary friction and delivers consistent pricing, adherence monitoring and real-time clinical review," the company added.

    Danish drugmaker Novo and its U.S. rival Lilly have been trying to eliminate unapproved, compounded versions, made by combining, mixing or altering drug ingredients, of their blockbuster weight-loss treatments.

    The drugmakers currently dominate the lucrative obesity treatment market, which analysts estimate could be worth $150 billion annually by the early 2030s, with their highly effective drugs designed to mimic the appetite-suppressing GLP-1 hormone.

    "Transparent initiatives like these enable more employers to opt in to coverage for authentic, FDA-approved GLP-1 medicines while providing people who need care with a seamless experience that allows them to prioritize their health," a Novo Nordisk spokesperson told Reuters.

    (Reporting by Mariam Sunny in Bengaluru; Editing by Krishna Chandra Eluri)

    Key Takeaways

    • •Waltz Health launches program for direct drug sales to employers.
    • •Novo Nordisk and Eli Lilly collaborate with Waltz Health.
    • •Program bypasses traditional drug sales channels.
    • •Focus on FDA-approved GLP-1 weight-loss drugs.
    • •Program aims to eliminate compounded drug versions.

    Frequently Asked Questions about Novo, Lilly collaborate with Waltz Health to sell weight-loss drugs directly to employers

    1What is a weight-loss drug?

    Weight-loss drugs are medications designed to help individuals lose weight by suppressing appetite, increasing feelings of fullness, or reducing fat absorption. They are often prescribed for obesity management.

    2What is the GLP-1 hormone?

    GLP-1 (glucagon-like peptide-1) is a hormone that plays a role in regulating appetite and blood sugar levels. It is often targeted by weight-loss medications to help control hunger and promote weight loss.

    More from Finance

    Explore more articles in the Finance category

    Image for Exclusive-At least 40% of Russia's oil export capacity halted, Reuters calculations show
    Exclusive-At Least 40% of Russia's Oil Export Capacity Halted, Reuters Calculations Show
    Image for Hungary's opposition Tisza party widens lead over Orban's Fidesz, poll says
    Hungary's Opposition Tisza Party Widens Lead Over Orban's Fidesz, Poll Says
    Image for Germany's Merz says public finances cannot offset all price rises from Iran war
    Germany's Merz Says Public Finances Cannot Offset All Price Rises From Iran War
    Image for Brazil unveils first supersonic fighter jet assembled in country
    Brazil Unveils First Supersonic Fighter Jet Assembled in Country
    Image for Netanyahu seeks to avoid snap vote as Iran war gives no boost in polls
    Netanyahu Seeks to Avoid Snap Vote as Iran War Gives No Boost in Polls
    Image for Volkswagen's Skoda brand to end China sales this year
    Volkswagen's Skoda Brand to End China Sales This Year
    Image for Climate investors give BP until April 1 to include resolution, threaten court
    Climate Investors Give Bp Until April 1 to Include Resolution, Threaten Court
    Image for Lille to host EU customs authority charged with fixing e-commerce parcel problems
    Lille to Host EU Customs Authority Charged With Fixing E-Commerce Parcel Problems
    Image for Russia evacuates 163 more staff from Iran's Bushehr nuclear plant, 300 remain
    Russia Evacuates 163 More Staff From Iran's Bushehr Nuclear Plant, 300 Remain
    Image for Hungary's Orban faces pivotal battle against ally-turned-foe
    Hungary's Orban Faces Pivotal Battle Against Ally-Turned-Foe
    Image for German finance minister sets out sweeping reform plans to boost growth
    German Finance Minister Sets Out Sweeping Reform Plans to Boost Growth
    Image for ISS urges investors to reject UniCredit pay report over CEO award
    Iss Urges Investors to Reject UniCredit Pay Report Over CEO Award
    View All Finance Posts
    Previous Finance PostADNOC's Covestro Takeover Gets Final Regulatory Approval in Germany
    Next Finance PostExclusive-Kering CEO Plans 'House of Dreams' Investment Arm to Help Trim Reliance on Gucci